Association Between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Risk of Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Jun 6

PMID 35665350

Authors

Liping Wang

Jinzhong Dong

Miao Xu

Li Li

Naibin Yang

Guoqing Qian

Affiliations

Soon will be listed here.

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a global health problem affecting more than a quarter of the entire adult population. Both monocytes and high-density lipoprotein cholesterol (HDL-C) were found to participate in the progression of hepatic inflammation and oxidative stress. We speculated that the monocyte-to-HDL-C ratio (MHR) may be associated with the risk of NAFLD.

Methods: We conducted a cross-sectional study using data from the National Health and Nutrition Examination Survey (NHANES) 2017-2018. NAFLD was identified using a controlled attenuation parameter (CAP) of ≥274 dB/m. Degree of liver fibrosis were assessed by liver stiffness measurement (LSM) and LSM values≥8.0, ≥ 9.7, and ≥13.7 kPa were defined as significant fibrosis (≥F2), advanced fibrosis (≥F3) and cirrhosis (F4), respectively. The association between MHR and the risk of NAFLD and liver fibrosis was estimated using weighted multivariable logistic regression. The non-linear relationship between MHR and the risk of NAFLD was further described using smooth curve fittings and threshold effect analysis.

Results: Of 4,319 participants, a total of 1,703 (39.4%) participants were diagnosed with NAFLD. After complete adjustment for potential confounders, MHR was positively associated with the risk of NAFLD (OR = 2.87, 95% CI: 1.95-4.22). The risk of NAFLD increased progressively as the MHR quarter increased ( for trend < 0.001). In subgroup analysis stratified by sex, a positive association existed in both sexes; Women displayed higher risk (men: OR = 2.12, 95% CI: 1.33-3.39; women: OR = 2.64, 95%CI: 1.40-4.97). MHR was positively associated with the risk of significant liver fibrosis (OR = 1.60, 95% CI: 1.08-2.37) and cirrhosis (OR = 1.83, 95% CI: 1.08-3.13), but not with advanced liver fibrosis (OR = 1.53, 95% CI: 0.98-2.39) after full adjustment for potential confounders. In the subgroup analysis by sex, the association between MHR and different degrees of liver fibrosis was significantly positive in women. When analyzing the relationship between MHR and NAFLD risk, a reverse U-shaped curve with an inflection point of 0.36 for MHR was found in women.

Conclusion: Higher MHR was associated with increased odds of NAFLD among Americans of both sexes. However, an association between MHR and liver fibrosis was found mainly among women.

Citing Articles

Clinical and Diagnostic Value of High-Density Lipoprotein-Based Inflammatory Indices and Lipid Ratios in Young Adults with Schizophrenia.

Chen L, Zheng C, Luan H, Chen X J Inflamm Res. 2024; 17:6363-6374.

PMID: 39296645 PMC: 11410031. DOI: 10.2147/JIR.S473528.

Monocyte distribution width as a promising biomarker for differential diagnosis of chronic hepatitis, cirrhosis, and hepatocellular carcinoma.

Lin S, Yang X, Yang X, Tang M, Yao X, Ye Y Front Immunol. 2024; 15:1406671.

PMID: 39021573 PMC: 11251903. DOI: 10.3389/fimmu.2024.1406671.

Association between monocyte-to-high-density lipoprotein-cholesterol ratio and gallstones in U.S. adults: findings from the National Health and Nutrition Examination Survey 2017-2020.

Liu X, Yan G, Xu B, Sun M Lipids Health Dis. 2024; 23(1):173.

PMID: 38849878 PMC: 11157827. DOI: 10.1186/s12944-024-02166-1.

Effect of Cytokeratin-18, C-peptide, MHR, and MACK-3 Biomarkers in Metabolic Dysfunction-Associated Fatty Liver Disease After Laparoscopic Sleeve Gastrectomy.

Hany M, Demerdash H, Abouelnasr A, Torensma B Biomark Insights. 2024; 19:11772719241256496.

PMID: 38836118 PMC: 11149444. DOI: 10.1177/11772719241256496.

The association between monocyte-to-high-density lipoprotein ratio and hyperuricemia: Results from 2009 to 2018.

Cao L, Wu C, Liu M, Zhang W, Chen H, Wang R Medicine (Baltimore). 2024; 103(17):e37713.

PMID: 38669360 PMC: 11049789. DOI: 10.1097/MD.0000000000037713.

References

Kim G, Lee H, Choe J, Kim M, Lee M, Chang H . Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2017; . DOI: 10.1016/j.jhep.2017.09.012. View

Daemen S, Gainullina A, Kalugotla G, He L, Chan M, Beals J . Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH. Cell Rep. 2021; 34(2):108626. PMC: 7877246. DOI: 10.1016/j.celrep.2020.108626. View

Sheka A, Adeyi O, Thompson J, Hameed B, Crawford P, Ikramuddin S . Nonalcoholic Steatohepatitis: A Review. JAMA. 2020; 323(12):1175-1183. DOI: 10.1001/jama.2020.2298. View

Huang D, El-Serag H, Loomba R . Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2020; 18(4):223-238. PMC: 8016738. DOI: 10.1038/s41575-020-00381-6. View

Huang H, Wang Q, Shi X, Chen Y, Shen C, Zhang J . Association between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. Mediators Inflamm. 2021; 2021:6642246. PMC: 8670965. DOI: 10.1155/2021/6642246. View

Roulot D, Czernichow S, Le Clesiau H, Costes J, Vergnaud A, Beaugrand M . Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008; 48(4):606-13. DOI: 10.1016/j.jhep.2007.11.020. View

Zhang J, Li Y, Zhou Y, Wang K, Pan C, Zhao Y . Monocyte to High-Density Lipoprotein Ratio: A Novel Predictive Marker of Disease Severity and Prognosis in Patients With Neuromyelitis Optica Spectrum Disorders. Front Neurol. 2021; 12:763793. PMC: 8580507. DOI: 10.3389/fneur.2021.763793. View

Netea M, Dominguez-Andres J, Barreiro L, Chavakis T, Divangahi M, Fuchs E . Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020; 20(6):375-388. PMC: 7186935. DOI: 10.1038/s41577-020-0285-6. View

Kazankov K, Barrera F, Moller H, Rosso C, Bugianesi E, David E . The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver Int. 2016; 36(10):1549-57. DOI: 10.1111/liv.13150. View

10.

Ciardullo S, Ballabeni C, Trevisan R, Perseghin G . Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population. Dig Liver Dis. 2021; 53(7):866-872. DOI: 10.1016/j.dld.2021.02.010. View

11.

Rada P, Gonzalez-Rodriguez A, Garcia-Monzon C, Valverde A . Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?. Cell Death Dis. 2020; 11(9):802. PMC: 7519685. DOI: 10.1038/s41419-020-03003-w. View

12.

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2019; 43(Suppl 1):S14-S31. DOI: 10.2337/dc20-S002. View

13.

Ciardullo S, Perseghin G . Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism. 2021; 121:154752. DOI: 10.1016/j.metabol.2021.154752. View

14.

Saemann M, Poglitsch M, Kopecky C, Haidinger M, Horl W, Weichhart T . The versatility of HDL: a crucial anti-inflammatory regulator. Eur J Clin Invest. 2010; 40(12):1131-43. DOI: 10.1111/j.1365-2362.2010.02361.x. View

15.

van der Heide D, Weiskirchen R, Bansal R . Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases. Front Immunol. 2019; 10:2852. PMC: 6901832. DOI: 10.3389/fimmu.2019.02852. View

16.

Ludwig J, Viggiano T, MCGILL D, Oh B . Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55(7):434-8. View

17.

Karlmark K, Weiskirchen R, Zimmermann H, Gassler N, Ginhoux F, Weber C . Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology. 2009; 50(1):261-74. DOI: 10.1002/hep.22950. View

18.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

19.

Sanyal A, Shankar S, Calle R, Samir A, Sirlin C, Sherlock S . Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project. Nat Med. 2022; 28(3):430-432. PMC: 9588405. DOI: 10.1038/s41591-021-01652-8. View

20.

Ciardullo S, Perseghin G . Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int. 2021; 41(6):1290-1293. DOI: 10.1111/liv.14828. View